News & analysis on the clinical development and manufacture of large molecule drugs
By Natalie Morrison
- Last updated on
His 30 year career includes his role as president and CEO ay Hoffmann-La Roche, where he led the North American pharmaceutical operations.
Abercrombie also serves on the board for Brickell Biotech.
“George’s proven industry experience in pharmaceutical product development and commercial operations will be a tremendous asset to our Board and management team as we advance our two late-stage product candidates and transition toward commercial-stage operations," said Vipin Garg, Tranzyme's president and CEO.